The Multidisciplinary Association for Psychedelic Studies has partnered with a New Jersey cannabis retailer in its first collaboration with the marijuana industry after four decades focused on academic and clinical research.
MAPS signed an education and outreach agreement with HoneyProjects, a three-location dispensary operator whose newest store opened August 29 in Elmwood Park. The partnership represents a departure from the nonprofit's traditional work with universities, medical institutions, and federal agencies including the Pentagon.
The deal focuses on consumer education rather than clinical trials or research protocols. HoneyProjects will host MAPS-developed educational materials and programming at its retail locations, aiming to inform cannabis customers about harm reduction, responsible use, and the broader therapeutic potential of psychoactive substances.
Why Retail Matters
MAPS has spent decades navigating FDA trials for MDMA-assisted therapy and funding psilocybin research at major universities. The organization's work with the Department of Defense on treating PTSD in veterans established its credentials in clinical settings. But retail cannabis represents a different frontier—direct consumer contact at the point of sale.
New Jersey's adult-use market launched in April 2022 and generated $187 million in sales during the first quarter of 2024. The state's regulatory framework requires dispensaries to provide educational resources, creating an opening for organizations like MAPS to reach consumers who might never encounter psychedelic therapy in clinical contexts.
HoneyProjects operates stores in Elmwood Park, Jersey City, and Eatontown. The company positions itself as education-focused, distinguishing its brand in a competitive market where more than 100 dispensaries now serve New Jersey's 9 million residents.
The Education Angle
The MAPS partnership will not involve cannabis research or product development. Instead, the nonprofit will provide educational content about substance use, mental health, and the evolving science around psychoactive compounds. For MAPS, it's a public health play—reaching people where they already purchase cannabis rather than waiting for them to seek clinical treatment.
The timing aligns with growing mainstream acceptance of both cannabis and psychedelics. Oregon and Colorado have legalized psilocybin therapy programs, while the FDA is reviewing MDMA-assisted therapy for PTSD. Cannabis rescheduling to Schedule III remains under federal consideration, potentially opening new research pathways.
For HoneyProjects, the MAPS affiliation offers credibility and differentiates its stores from competitors focused purely on product selection and price. New Jersey's saturated market has driven down wholesale cannabis prices by 40% since 2023, pushing retailers to compete on experience and education rather than just inventory.
What Comes Next
Neither MAPS nor HoneyProjects disclosed financial terms of the partnership or specified which educational programs will launch first. The agreement covers all three HoneyProjects locations, with potential expansion if the initial rollout succeeds.
The partnership could signal a broader strategy shift for MAPS as psychedelic therapy moves from research labs toward commercialization. With the FDA expected to rule on MDMA therapy by August 2024, the organization may be preparing for a future where psychedelic education reaches beyond academic conferences and medical journals.
For cannabis retailers, partnerships with research-focused nonprofits offer a way to build legitimacy in an industry still fighting federal prohibition and banking restrictions. Whether that model scales beyond New Jersey depends on how effectively MAPS translates decades of clinical expertise into retail-friendly consumer education.
This article is based on original reporting by hightimes.com.
